Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

An Observational Prospective Natural History Study of Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have largely looked at members of large families at a single time point. Researchers want to learn more about the disease at an individual level.

Objective: To understand the natural history of changes in the retina that occur in people with STDG3.

Eligibility: People ages 10 and older with STDG3 due to a variant in the ELOVL4 gene.

Design: Participants will have 6 visits. First they will have a screening visit, followed by a baseline visit. Then they will have a visit 6 months later. Then they will have a visit 1, 2, and 3 years after the first visit. Visits will last 4 to 8 hours. Visits will include the following: Medical history and physical exam. Complete eye exam. Participants' eye pressure and ability to see letters on a vision chart will be tested. Their pupils will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Questions about participants' family history, especially the presence of eye disease. Visual field test. Participants will be seated in front of a large dome and asked to press a button when they see a light within the dome. Electroretinogram. Participants will sit in the dark with their eyes patched for 30 minutes. Then they will wear special contact lenses and watch flashing lights. Optical coherence tomography. Cross-sectional pictures will be taken of participants' retinas. Fundus autofluorescence. Blue light will be shone into participants eyes to assess the health of the retina....

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 100
Healthy Volunteers: f
View:

⁃ To be eligible, the following inclusion criteria must be met, where applicable.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Participant must be at least ten years of age.

• Ability to perform required functional testing and ophthalmic imaging.

• A mutation in ELOVL4 with a typical clinical presentation of Stargardt-like macular dystrophy.

• Participant (or legal guardian) must understand and sign the protocol s informed consent document.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Daniel W Claus, R.N.
daniel.claus@nih.gov
(301) 451-1621
Backup
Brett G Jeffrey, Ph.D.
jeffreybg@mail.nih.gov
(301) 402-2391
Time Frame
Start Date: 2022-04-19
Estimated Completion Date: 2028-07-16
Participants
Target number of participants: 25
Treatments
Affected
Patients with Stargardt-like macular dystrophy 3 who are \>= 10 years of age.
Related Therapeutic Areas
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Leads: National Eye Institute (NEI)
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Who is this study for: Patients with Age-Related Macular Degeneration
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: iPSC-Derived Retinal Pigment Epithelium/Poly Lactic-Co-Glycolic Acid Transplantation
Study Phase: Phase 1/Phase 2

JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862

JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862

Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Phase: Phase 2

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls

Enrollment Status: Recruiting
Publish Date: October 07, 2025
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved